Investors & Media

Press Releases

Press Releases

Date Title View
November 8, 2023 Sage Therapeutics to Present at Upcoming November Investor Conferences
November 7, 2023 Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
October 24, 2023 Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
October 18, 2023 Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
September 6, 2023 Sage Therapeutics to Present at Upcoming September Investor Conferences
August 31, 2023 Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement
August 7, 2023 Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
August 4, 2023 Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023
August 4, 2023 FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
June 5, 2023 Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
Displaying 1 - 10 of 23